The S&P/ASX 200 Index (ASX: XJO) is 0.36% lower at the time of writing on Tuesday morning. Over the year, the index is 8.5% higher, and there are signals that the index could end 2025 at an all-time high.
But there are some stocks that are set to far outpace the index.
Here are two ASX 200-listed shares that are tipped to hike over 80% in the next 12 months.
Image source: Getty Images
NextDC Ltd (ASX: NXT)
The NextDC shares price is trading 0.19% lower at $15.79 at the time of writing on Tuesday morning. For the year, the shares have dropped 3.90% thanks to a share price dip to a two-year low in April this year. Since then, the share price has recovered an impressive 57.27%.
NextDC is benefitting from an explosion of demand for cloud computing, AI adoption, and general digital infrastructure needs. This, combined with its network-rich connectivity ecosystem, positions the company well to experience significant growth prospects.
But analysts think there is still a long way for the company's shares to run. According to TradingView data, 13 out of 15 analysts have a buy or strong buy rating on the shares with a maximum target price of $28.66. That's a potential upside of a huge 81.28% at the time of writing.
UBS has a buy rating on Nextdc shares, with a price target of $21.45. That implies a possible rise of 35.8% over the next year.
Macquarie analysts are also a fan of the ASX 200 tech stock but are a little more conservative in their outlook. They hold an outperform rating and $20.90 price target on its shares. This implies a potential upside of 32.4%.
Telix Pharmaceuticals Ltd (ASX: TLX)
The Telix Pharmaceuticals share price is 1.39% lower at the time of writing at $15.59 a piece.
The commercial-stage biopharmaceutical company's shares have plunged 46.7% over the past 6 months following an issue with the United States Food and Drug Administration (FDA).
The FDA said it had identified deficiencies relating to the Chemistry, Manufacturing, and Controls (CMC) package. The company provided a statement on 28 August, saying it believes these concerns are readily addressable and submission remediation will begin immediately.
The good news is that analysts think the tide is about to turn for the beaten-down ASX 200 share. TradingView data shows 14 out of 15 analysts have a buy or strong buy rating on the shares, with a maximum target price of $35. That represents a whopping potential 123.6% upside for investors over the next 12 months.
UBS is bullish on the stock. It has a buy rating on the ASX biotech share, with a price target of $31. Bell Potter is confident in the company's future but has a more conservative target price of $23.
